Researchers in Dr. James Ford’s lab have developed methods of using bis(thiohydrazide amide) compounds to treat patients with DNA-repair compromised cancers. Many cancers are aggressive and have high rates of relapse following chemotherapy. Among such cancers is the basal-like breast cancer subtype which includes hereditary breast cancers due to germline mutations in BRCA1. These cancers tend to be relatively insensitive to existing “targeted” therapeutics and thus additional treatment options are necessary. To help provide new treatment options the inventors took advantage of their recent finding that these cancers have an impaired ability to repair oxidative DNA damage and thus the cancers are selectively sensitive to bis(thiohydrazide amide) compounds that produce elevated levels of oxidative DNA damage. This technology provides methods to treat patients that have aggressive DNA repair-compromised cancers.Stage of research
Using in vitro
cellular assays, the inventors have shown that a bis(thiohydrazide amide) compound, induced cell death in up to 75% of basal-like breast cancer cells and in up to 95% of BRCA1-mutated breast cancer cells. Normal breast cells and luminal breast cancer cells remained unaffected. Thus bis(thiohydrazide amide) compounds may be a useful therapeutic option for DNA-repair compromised cancers.